fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Cefuroxime axetil

Form:

9 of 9 products shown

7 general benefit · 2 not a benefit

Ceftin · DIN 02212307 · 125 mg/5 mL · suspension

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Ceftin · DIN 02212307 Manufacturer: Sandoz Canada Inc.; listing date 1998-10-21 Health Canada: Marketed since 2022-10-28 · brand CEFTIN · ATC J01DC02 CEFUROXIME · form Granules for suspension · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 125 MG/5ML · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ceftin: Formulary list price $0.18 per unit (the source does not state the unit; exact figure $0.1830). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02212307)

Source record
DIN 02212307: Ceftin Raw flags: sec3=Y Item: 081228079; group id 42; item number 0091; lccId None; manufacturer id SDZ Source form: Susp; strength: 125mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1830; ministry $0.1830 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02212307 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43089
Shortage status: resolved shortage (ended May 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212307
Shortage record checked October 6, 2026

Apo-Cefuroxime · DIN 02244393 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Cefuroxime · DIN 02244393 Manufacturer: Apotex Inc.; listing date 2002-04-04 Daily cost (source): $0.8388 Health Canada: Marketed since 2001-08-29 · brand APO-CEFUROXIME · ATC J01DC02 CEFUROXIME · form Tablet · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 250 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Cefuroxime: Formulary list price $0.42 per unit (the source does not state the unit; exact figure $0.4194). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244393)

Source record
DIN 02244393: Apo-Cefuroxime Raw flags: sec3=Y Item: 081228064; group id 42; item number 0092; lccId None; manufacturer id APX Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.4194; ministry $0.4194 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244393 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68362
Interchangeable products
Auro-Cefuroxime · DIN 02344823 · $0.4194 Ceftin · DIN 02212277 · not recorded Jamp Cefuroxime · DIN 02547198 · $0.4194
Shortage status: anticipated shortage (last updated August 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244393
Shortage record checked October 6, 2026

Auro-Cefuroxime · DIN 02344823 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Cefuroxime · DIN 02344823 Manufacturer: Auro Pharma Inc.; listing date 2012-05-29 Daily cost (source): $0.8388 Health Canada: Marketed since 2021-01-11 · brand AURO-CEFUROXIME · ATC J01DC02 CEFUROXIME · form Tablet · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 250 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Cefuroxime: Formulary list price $0.42 per unit (the source does not state the unit; exact figure $0.4194). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02344823)

Source record
DIN 02344823: Auro-Cefuroxime Raw flags: sec3=Y Item: 081228064; group id 42; item number 0092; lccId None; manufacturer id AUR Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.4194; ministry $0.4194 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02344823 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83030
Interchangeable products
Apo-Cefuroxime · DIN 02244393 · $0.4194 Ceftin · DIN 02212277 · not recorded Jamp Cefuroxime · DIN 02547198 · $0.4194
Shortage status: resolved shortage (ended January 12, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02344823
Shortage record checked October 6, 2026

Jamp Cefuroxime · DIN 02547198 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Cefuroxime · DIN 02547198 Manufacturer: Jamp Pharma Corporation; listing date 2024-11-29 Daily cost (source): $0.8388 Health Canada: Marketed since 2024-09-27 · brand JAMP CEFUROXIME · ATC J01DC02 CEFUROXIME · form Tablet · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 250 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Cefuroxime: Formulary list price $0.42 per unit (the source does not state the unit; exact figure $0.4194). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547198)

Source record
DIN 02547198: Jamp Cefuroxime Raw flags: sec3=Y Item: 081228064; group id 42; item number 0092; lccId None; manufacturer id JPC Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.4194; ministry $0.4194 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547198 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103583
Interchangeable products
Apo-Cefuroxime · DIN 02244393 · $0.4194 Auro-Cefuroxime · DIN 02344823 · $0.4194 Ceftin · DIN 02212277 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547198
Shortage record checked October 6, 2026

Apo-Cefuroxime · DIN 02244394 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Cefuroxime · DIN 02244394 Manufacturer: Apotex Inc.; listing date 2002-04-04 Daily cost (source): $1.6616 Health Canada: Marketed since 2001-08-29 · brand APO-CEFUROXIME · ATC J01DC02 CEFUROXIME · form Tablet · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Cefuroxime: Formulary list price $0.83 per unit (the source does not state the unit; exact figure $0.8308). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244394)

Source record
DIN 02244394: Apo-Cefuroxime Raw flags: sec3=Y Item: 081228065; group id 42; item number 0093; lccId None; manufacturer id APX Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.8308; ministry $0.8308 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244394 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68363
Interchangeable products
Auro-Cefuroxime · DIN 02344831 · $0.8308 Ceftin · DIN 02212285 · not recorded Jamp Cefuroxime · DIN 02547201 · $0.8308
Shortage status: resolved shortage (ended April 13, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244394
Shortage record checked October 6, 2026

Auro-Cefuroxime · DIN 02344831 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Cefuroxime · DIN 02344831 Manufacturer: Auro Pharma Inc.; listing date 2012-05-29 Daily cost (source): $1.6616 Health Canada: Marketed since 2021-01-11 · brand AURO-CEFUROXIME · ATC J01DC02 CEFUROXIME · form Tablet · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 500 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Cefuroxime: Formulary list price $0.83 per unit (the source does not state the unit; exact figure $0.8308). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02344831)

Source record
DIN 02344831: Auro-Cefuroxime Raw flags: sec3=Y Item: 081228065; group id 42; item number 0093; lccId None; manufacturer id AUR Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.8308; ministry $0.8308 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02344831 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83031
Interchangeable products
Apo-Cefuroxime · DIN 02244394 · $0.8308 Ceftin · DIN 02212285 · not recorded Jamp Cefuroxime · DIN 02547201 · $0.8308
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02344831
Shortage record checked October 6, 2026

Jamp Cefuroxime · DIN 02547201 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Cefuroxime · DIN 02547201 Manufacturer: Jamp Pharma Corporation; listing date 2024-11-29 Daily cost (source): $1.6616 Health Canada: Marketed since 2024-09-27 · brand JAMP CEFUROXIME · ATC J01DC02 CEFUROXIME · form Tablet · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 500 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Cefuroxime: Formulary list price $0.83 per unit (the source does not state the unit; exact figure $0.8308). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547201)

Source record
DIN 02547201: Jamp Cefuroxime Raw flags: sec3=Y Item: 081228065; group id 42; item number 0093; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.8308; ministry $0.8308 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547201 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103584
Interchangeable products
Apo-Cefuroxime · DIN 02244394 · $0.8308 Auro-Cefuroxime · DIN 02344831 · $0.8308 Ceftin · DIN 02212285 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547201
Shortage record checked October 6, 2026

Ceftin · DIN 02212277 · 250 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-20 — choose a marketed DIN from the same-category list.Discontinued July 20, 2020 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-20 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-07-20 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Ceftin · DIN 02212277 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-10-21 Daily cost (source): $0.8388 Health Canada: Cancelled post market since 2020-07-20 · brand CEFTIN - TAB 250MG · ATC J01DC02 CEFUROXIME · form Tablet · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 250 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ceftin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02212277)

Source record
DIN 02212277: Ceftin Raw flags: notABenefit=Y, sec3=Y Item: 081228064; group id 42; item number 0092; lccId None; manufacturer id GSK Source form: Tab; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02212277 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43086
Interchangeable products
Apo-Cefuroxime · DIN 02244393 · $0.4194 Auro-Cefuroxime · DIN 02344823 · $0.4194 Jamp Cefuroxime · DIN 02547198 · $0.4194
Shortage status: discontinued (July 20, 2020, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212277
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 20, 2020 — choose a marketed DIN from the same-category list.

Ceftin · DIN 02212285 · 500 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-20 — choose a marketed DIN from the same-category list.Discontinued July 20, 2020 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-20 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-07-20 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Ceftin · DIN 02212285 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-10-21 Daily cost (source): $1.6616 Health Canada: Cancelled post market since 2020-07-20 · brand CEFTIN - TAB 500MG · ATC J01DC02 CEFUROXIME · form Tablet · route Oral · ingredients CEFUROXIME (CEFUROXIME AXETIL) 500 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ceftin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02212285)

Source record
DIN 02212285: Ceftin Raw flags: notABenefit=Y, sec3=Y Item: 081228065; group id 42; item number 0093; lccId None; manufacturer id GSK Source form: Tab; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02212285 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43087
Interchangeable products
Apo-Cefuroxime · DIN 02244394 · $0.8308 Auro-Cefuroxime · DIN 02344831 · $0.8308 Jamp Cefuroxime · DIN 02547201 · $0.8308
Shortage status: discontinued (July 20, 2020, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212285
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 20, 2020 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01D, J01DC): coverage varies; not interchangeable

  • Cefprozil (Ran-Cefprozil): general benefit, not a benefit
  • Cefoxitin (Mefoxin): not a benefit
  • Cefadroxil (Duricef): general benefit, not a benefit
  • Cefixime (Suprax): general benefit
  • Ceftriaxone (Rocephin): general benefit, not a benefit
  • Cephalexin (Ceporex): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: moderately infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. PENICILLIN V (POTASSIUM) · Listed, not a benefit (2), General benefit (2) Indications PEN-VK (Penicillin V Potassium (Phenoxymethylpenicillin Potassium)) is indicated for: • Mild to moderately severe infections caused by penicillin V sensitive microorganisms including streptococcal pharyngitis, staphylococcal infection without bacteremia and pneumococcal infections. PM: https://pdf.hres.ca/dpd_pm/00081311.PDF; date August 1, 2025; DIN 00642215; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications CEFTIN (cefuroxime axetil for oral suspension) is indicated for the treatment of patients with mild to moderately severe infections caused by susceptible strains of the designated organisms in the following diseases: • Upper Respiratory Tract Infections: Pharyngitis and tonsillitis caused by Streptococcus pyogenes. Otitis Media caused by Streptococcus pneumoniae, Streptococcus pyogenes (group A beta-hemolytic streptococci), Haemophilus influenzae (beta-lactamase negative and beta-lactamase positive strains) or Moraxella catarrhalis. • Skin Structure Infections: Skin structure infections caused by Staphylococcus aureus (methicillin susceptible), Streptococcus pyogenes or Streptococcus agalactiae. Susceptibility to cefuroxime axetil will vary with geography and time. Cefuroxime axetil should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data (see 15. Microbiology). Bacteriologic studies to determine the causative organism and its susceptibility to cefuroxime should be performed. Once these results become available antibiotic treatment should be adjusted if required. To reduce the development of d… https://pdf.hres.ca/dpd_pm/00081954.PDF PM date: 2025-10-03 Source product: CEFTIN; DIN 02212307; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ceftin · DIN 02212277 Shortage status: discontinued (2020-07-20, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212277

Check this DIN again

Ceftin · DIN 02212285 Shortage status: discontinued (2020-07-20, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212285

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Ceftin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026